nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—ERBB3—chronic obstructive pulmonary disease	0.305	0.541	CbGaD
Gefitinib—EGFR—chronic obstructive pulmonary disease	0.137	0.243	CbGaD
Gefitinib—CYP1A1—chronic obstructive pulmonary disease	0.0782	0.139	CbGaD
Gefitinib—ALB—chronic obstructive pulmonary disease	0.0435	0.0773	CbGaD
Gefitinib—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0227	0.0951	CbGbCtD
Gefitinib—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0227	0.0951	CbGbCtD
Gefitinib—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0189	0.079	CbGbCtD
Gefitinib—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0189	0.079	CbGbCtD
Gefitinib—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0173	0.0723	CbGbCtD
Gefitinib—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0173	0.0723	CbGbCtD
Gefitinib—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0154	0.0644	CbGbCtD
Gefitinib—ALB—Prednisone—chronic obstructive pulmonary disease	0.0147	0.0616	CbGbCtD
Gefitinib—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0145	0.0606	CbGbCtD
Gefitinib—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0143	0.0599	CbGbCtD
Gefitinib—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0098	0.041	CbGbCtD
Gefitinib—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.00955	0.0399	CbGbCtD
Gefitinib—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.00935	0.0391	CbGbCtD
Gefitinib—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.00833	0.0348	CbGbCtD
Gefitinib—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.00816	0.0341	CbGbCtD
Gefitinib—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.00771	0.0322	CbGbCtD
Gefitinib—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00489	0.0204	CbGbCtD
Gefitinib—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00462	0.0193	CbGbCtD
Gefitinib—MAP3K19—respiratory system—chronic obstructive pulmonary disease	0.00177	0.0524	CbGeAlD
Gefitinib—CSNK1E—respiratory system—chronic obstructive pulmonary disease	0.00138	0.0408	CbGeAlD
Gefitinib—ERBB3—respiratory system—chronic obstructive pulmonary disease	0.00133	0.0393	CbGeAlD
Gefitinib—MKNK2—respiratory system—chronic obstructive pulmonary disease	0.00127	0.0374	CbGeAlD
Gefitinib—ERBB3—connective tissue—chronic obstructive pulmonary disease	0.00117	0.0346	CbGeAlD
Gefitinib—CHEK2—lung—chronic obstructive pulmonary disease	0.00116	0.0341	CbGeAlD
Gefitinib—CSNK1E—bronchus—chronic obstructive pulmonary disease	0.00114	0.0336	CbGeAlD
Gefitinib—IRAK4—bronchus—chronic obstructive pulmonary disease	0.00112	0.033	CbGeAlD
Gefitinib—MKNK2—connective tissue—chronic obstructive pulmonary disease	0.00111	0.0329	CbGeAlD
Gefitinib—MKNK2—bronchus—chronic obstructive pulmonary disease	0.00104	0.0308	CbGeAlD
Gefitinib—IRAK1—bronchus—chronic obstructive pulmonary disease	0.00104	0.0308	CbGeAlD
Gefitinib—STK10—respiratory system—chronic obstructive pulmonary disease	0.00103	0.0304	CbGeAlD
Gefitinib—MKNK1—bronchus—chronic obstructive pulmonary disease	0.00103	0.0304	CbGeAlD
Gefitinib—CSNK1E—trachea—chronic obstructive pulmonary disease	0.00102	0.0301	CbGeAlD
Gefitinib—MKNK2—smooth muscle tissue—chronic obstructive pulmonary disease	0.00102	0.0301	CbGeAlD
Gefitinib—IRAK1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00102	0.0301	CbGeAlD
Gefitinib—IRAK4—trachea—chronic obstructive pulmonary disease	0.001	0.0297	CbGeAlD
Gefitinib—ERBB3—trachea—chronic obstructive pulmonary disease	0.000984	0.0291	CbGeAlD
Gefitinib—MAP3K19—lung—chronic obstructive pulmonary disease	0.000942	0.0278	CbGeAlD
Gefitinib—MKNK2—trachea—chronic obstructive pulmonary disease	0.000936	0.0276	CbGeAlD
Gefitinib—STK10—bronchus—chronic obstructive pulmonary disease	0.000847	0.025	CbGeAlD
Gefitinib—EGFR—lung—chronic obstructive pulmonary disease	0.000762	0.0225	CbGeAlD
Gefitinib—MAP2K5—bronchus—chronic obstructive pulmonary disease	0.000757	0.0224	CbGeAlD
Gefitinib—Lapatinib—EGFR—chronic obstructive pulmonary disease	0.000749	0.142	CrCbGaD
Gefitinib—CSNK1E—lung—chronic obstructive pulmonary disease	0.000733	0.0216	CbGeAlD
Gefitinib—IRAK4—lung—chronic obstructive pulmonary disease	0.000721	0.0213	CbGeAlD
Gefitinib—ERBB3—lung—chronic obstructive pulmonary disease	0.000707	0.0209	CbGeAlD
Gefitinib—MAP2K5—trachea—chronic obstructive pulmonary disease	0.00068	0.0201	CbGeAlD
Gefitinib—MKNK2—lung—chronic obstructive pulmonary disease	0.000672	0.0199	CbGeAlD
Gefitinib—IRAK1—lung—chronic obstructive pulmonary disease	0.000672	0.0199	CbGeAlD
Gefitinib—MKNK1—lung—chronic obstructive pulmonary disease	0.000664	0.0196	CbGeAlD
Gefitinib—Vandetanib—ERBB3—chronic obstructive pulmonary disease	0.000551	0.104	CrCbGaD
Gefitinib—STK10—lung—chronic obstructive pulmonary disease	0.000547	0.0162	CbGeAlD
Gefitinib—Afatinib—EGFR—chronic obstructive pulmonary disease	0.000531	0.101	CrCbGaD
Gefitinib—Bosutinib—ERBB3—chronic obstructive pulmonary disease	0.000516	0.0976	CrCbGaD
Gefitinib—MAP2K5—lung—chronic obstructive pulmonary disease	0.000488	0.0144	CbGeAlD
Gefitinib—CYP1A1—respiratory system—chronic obstructive pulmonary disease	0.000425	0.0125	CbGeAlD
Gefitinib—CYP3A5—respiratory system—chronic obstructive pulmonary disease	0.000415	0.0123	CbGeAlD
Gefitinib—CSNK1E—Danazol—Prednisone—chronic obstructive pulmonary disease	0.000403	0.248	CbGdCrCtD
Gefitinib—ORM1—lung—chronic obstructive pulmonary disease	0.000396	0.0117	CbGeAlD
Gefitinib—Erlotinib—EGFR—chronic obstructive pulmonary disease	0.000375	0.071	CrCbGaD
Gefitinib—CYP1A1—bronchus—chronic obstructive pulmonary disease	0.00035	0.0103	CbGeAlD
Gefitinib—Mediastinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000334	0.00416	CcSEcCtD
Gefitinib—Urticaria—Roflumilast—chronic obstructive pulmonary disease	0.000333	0.00414	CcSEcCtD
Gefitinib—Arrhythmia—Tiotropium—chronic obstructive pulmonary disease	0.000331	0.00412	CcSEcCtD
Gefitinib—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.000331	0.00412	CcSEcCtD
Gefitinib—Pneumonia—Montelukast—chronic obstructive pulmonary disease	0.000328	0.00409	CcSEcCtD
Gefitinib—Infestation NOS—Montelukast—chronic obstructive pulmonary disease	0.000326	0.00406	CcSEcCtD
Gefitinib—Infestation—Montelukast—chronic obstructive pulmonary disease	0.000326	0.00406	CcSEcCtD
Gefitinib—Conjunctivitis—Formoterol—chronic obstructive pulmonary disease	0.000324	0.00403	CcSEcCtD
Gefitinib—Conjunctivitis—Arformoterol—chronic obstructive pulmonary disease	0.000324	0.00403	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Montelukast—chronic obstructive pulmonary disease	0.000324	0.00403	CcSEcCtD
Gefitinib—Malnutrition—Tiotropium—chronic obstructive pulmonary disease	0.000323	0.00402	CcSEcCtD
Gefitinib—Haematuria—Arformoterol—chronic obstructive pulmonary disease	0.000318	0.00396	CcSEcCtD
Gefitinib—Haematuria—Formoterol—chronic obstructive pulmonary disease	0.000318	0.00396	CcSEcCtD
Gefitinib—Conjunctivitis—Montelukast—chronic obstructive pulmonary disease	0.000317	0.00395	CcSEcCtD
Gefitinib—CYP1A1—trachea—chronic obstructive pulmonary disease	0.000314	0.00927	CbGeAlD
Gefitinib—Hepatobiliary disease—Montelukast—chronic obstructive pulmonary disease	0.000309	0.00384	CcSEcCtD
Gefitinib—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.000308	0.00384	CcSEcCtD
Gefitinib—Epistaxis—Montelukast—chronic obstructive pulmonary disease	0.000308	0.00383	CcSEcCtD
Gefitinib—Stomatitis—Salbutamol—chronic obstructive pulmonary disease	0.000307	0.00382	CcSEcCtD
Gefitinib—Conjunctivitis—Salbutamol—chronic obstructive pulmonary disease	0.000306	0.00381	CcSEcCtD
Gefitinib—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.0003	0.00374	CcSEcCtD
Gefitinib—Haematuria—Salbutamol—chronic obstructive pulmonary disease	0.0003	0.00374	CcSEcCtD
Gefitinib—Epistaxis—Salbutamol—chronic obstructive pulmonary disease	0.000297	0.0037	CcSEcCtD
Gefitinib—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.000295	0.00368	CcSEcCtD
Gefitinib—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.000295	0.00368	CcSEcCtD
Gefitinib—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.000295	0.00367	CcSEcCtD
Gefitinib—Oedema peripheral—Formoterol—chronic obstructive pulmonary disease	0.000295	0.00367	CcSEcCtD
Gefitinib—Oedema peripheral—Arformoterol—chronic obstructive pulmonary disease	0.000295	0.00367	CcSEcCtD
Gefitinib—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.000293	0.00365	CcSEcCtD
Gefitinib—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.000293	0.00365	CcSEcCtD
Gefitinib—Hepatitis—Montelukast—chronic obstructive pulmonary disease	0.000293	0.00365	CcSEcCtD
Gefitinib—Vandetanib—VEGFA—chronic obstructive pulmonary disease	0.000293	0.0555	CrCbGaD
Gefitinib—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.000289	0.0036	CcSEcCtD
Gefitinib—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.000287	0.00358	CcSEcCtD
Gefitinib—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.000286	0.00357	CcSEcCtD
Gefitinib—Haemoglobin—Salbutamol—chronic obstructive pulmonary disease	0.000284	0.00354	CcSEcCtD
Gefitinib—Haemorrhage—Salbutamol—chronic obstructive pulmonary disease	0.000282	0.00352	CcSEcCtD
Gefitinib—Cough—Tiotropium—chronic obstructive pulmonary disease	0.000282	0.00351	CcSEcCtD
Gefitinib—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.000279	0.00347	CcSEcCtD
Gefitinib—Acne—Prednisone—chronic obstructive pulmonary disease	0.000279	0.00347	CcSEcCtD
Gefitinib—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.000278	0.00346	CcSEcCtD
Gefitinib—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.000278	0.00346	CcSEcCtD
Gefitinib—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000277	0.00345	CcSEcCtD
Gefitinib—Erythema multiforme—Montelukast—chronic obstructive pulmonary disease	0.000277	0.00345	CcSEcCtD
Gefitinib—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.000277	0.00345	CcSEcCtD
Gefitinib—Shock—Aminophylline—chronic obstructive pulmonary disease	0.000275	0.00342	CcSEcCtD
Gefitinib—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000274	0.00341	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.000273	0.0034	CcSEcCtD
Gefitinib—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.000272	0.00339	CcSEcCtD
Gefitinib—Minaprine—SLC6A4—chronic obstructive pulmonary disease	0.000271	0.0513	CrCbGaD
Gefitinib—Thrombophlebitis—Prednisolone—chronic obstructive pulmonary disease	0.00027	0.00337	CcSEcCtD
Gefitinib—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00027	0.00336	CcSEcCtD
Gefitinib—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00027	0.00336	CcSEcCtD
Gefitinib—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000269	0.00335	CcSEcCtD
Gefitinib—Arrhythmia—Arformoterol—chronic obstructive pulmonary disease	0.000267	0.00333	CcSEcCtD
Gefitinib—Arrhythmia—Formoterol—chronic obstructive pulmonary disease	0.000267	0.00333	CcSEcCtD
Gefitinib—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000266	0.00332	CcSEcCtD
Gefitinib—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.000266	0.00331	CcSEcCtD
Gefitinib—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000264	0.00329	CcSEcCtD
Gefitinib—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000264	0.00329	CcSEcCtD
Gefitinib—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000264	0.00328	CcSEcCtD
Gefitinib—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000262	0.00326	CcSEcCtD
Gefitinib—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000262	0.00326	CcSEcCtD
Gefitinib—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000261	0.00325	CcSEcCtD
Gefitinib—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.00026	0.00324	CcSEcCtD
Gefitinib—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.00026	0.00324	CcSEcCtD
Gefitinib—Shock—Tiotropium—chronic obstructive pulmonary disease	0.000259	0.00323	CcSEcCtD
Gefitinib—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000258	0.00322	CcSEcCtD
Gefitinib—CSNK1E—Dexamethasone—Prednisone—chronic obstructive pulmonary disease	0.000257	0.158	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Prednisone—chronic obstructive pulmonary disease	0.000257	0.158	CbGdCrCtD
Gefitinib—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.000256	0.00319	CcSEcCtD
Gefitinib—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000256	0.00319	CcSEcCtD
Gefitinib—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000255	0.00317	CcSEcCtD
Gefitinib—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.000252	0.00314	CcSEcCtD
Gefitinib—CSNK1E—Betamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000251	0.154	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000251	0.154	CbGdCrCtD
Gefitinib—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000249	0.0031	CcSEcCtD
Gefitinib—Ulcer—Prednisone—chronic obstructive pulmonary disease	0.000248	0.00309	CcSEcCtD
Gefitinib—Vandetanib—EGFR—chronic obstructive pulmonary disease	0.000247	0.0468	CrCbGaD
Gefitinib—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000246	0.00306	CcSEcCtD
Gefitinib—Dermatitis bullous—Prednisolone—chronic obstructive pulmonary disease	0.000245	0.00305	CcSEcCtD
Gefitinib—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000243	0.00302	CcSEcCtD
Gefitinib—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000238	0.00296	CcSEcCtD
Gefitinib—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000238	0.00296	CcSEcCtD
Gefitinib—ABCG2—lung—chronic obstructive pulmonary disease	0.000238	0.00702	CbGeAlD
Gefitinib—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000235	0.00292	CcSEcCtD
Gefitinib—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000235	0.00292	CcSEcCtD
Gefitinib—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000233	0.0029	CcSEcCtD
Gefitinib—Bosutinib—EGFR—chronic obstructive pulmonary disease	0.000231	0.0438	CrCbGaD
Gefitinib—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000228	0.00284	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000227	0.00283	CcSEcCtD
Gefitinib—Cough—Formoterol—chronic obstructive pulmonary disease	0.000227	0.00283	CcSEcCtD
Gefitinib—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.00283	CcSEcCtD
Gefitinib—CYP1A1—lung—chronic obstructive pulmonary disease	0.000226	0.00666	CbGeAlD
Gefitinib—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000225	0.0028	CcSEcCtD
Gefitinib—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000225	0.0028	CcSEcCtD
Gefitinib—Cough—Montelukast—chronic obstructive pulmonary disease	0.000223	0.00277	CcSEcCtD
Gefitinib—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000222	0.00276	CcSEcCtD
Gefitinib—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.00276	CcSEcCtD
Gefitinib—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000221	0.00275	CcSEcCtD
Gefitinib—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000221	0.00275	CcSEcCtD
Gefitinib—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000221	0.00652	CbGeAlD
Gefitinib—CYP3A5—lung—chronic obstructive pulmonary disease	0.00022	0.00651	CbGeAlD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00022	0.00274	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00022	0.00274	CcSEcCtD
Gefitinib—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000217	0.0027	CcSEcCtD
Gefitinib—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000217	0.0027	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000216	0.00269	CcSEcCtD
Gefitinib—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000215	0.00268	CcSEcCtD
Gefitinib—Erlotinib—CYP1A1—chronic obstructive pulmonary disease	0.000215	0.0406	CrCbGaD
Gefitinib—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000215	0.00267	CcSEcCtD
Gefitinib—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.00267	CcSEcCtD
Gefitinib—Infection—Formoterol—chronic obstructive pulmonary disease	0.000211	0.00263	CcSEcCtD
Gefitinib—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000211	0.00263	CcSEcCtD
Gefitinib—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000209	0.00261	CcSEcCtD
Gefitinib—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000208	0.0026	CcSEcCtD
Gefitinib—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000208	0.0026	CcSEcCtD
Gefitinib—Minaprine—HTR2A—chronic obstructive pulmonary disease	0.000208	0.0394	CrCbGaD
Gefitinib—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000208	0.00259	CcSEcCtD
Gefitinib—Erlotinib—CYP1A2—chronic obstructive pulmonary disease	0.000207	0.0392	CrCbGaD
Gefitinib—Infection—Montelukast—chronic obstructive pulmonary disease	0.000207	0.00258	CcSEcCtD
Gefitinib—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000206	0.00257	CcSEcCtD
Gefitinib—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000206	0.00257	CcSEcCtD
Gefitinib—CHEK2—Danazol—Prednisone—chronic obstructive pulmonary disease	0.000206	0.127	CbGdCrCtD
Gefitinib—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000206	0.00256	CcSEcCtD
Gefitinib—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000205	0.00255	CcSEcCtD
Gefitinib—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000204	0.00254	CcSEcCtD
Gefitinib—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000204	0.00254	CcSEcCtD
Gefitinib—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000202	0.00252	CcSEcCtD
Gefitinib—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000199	0.00248	CcSEcCtD
Gefitinib—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000199	0.00247	CcSEcCtD
Gefitinib—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000199	0.00247	CcSEcCtD
Gefitinib—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000198	0.00247	CcSEcCtD
Gefitinib—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000198	0.00246	CcSEcCtD
Gefitinib—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000197	0.00246	CcSEcCtD
Gefitinib—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000197	0.00245	CcSEcCtD
Gefitinib—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.000197	0.00245	CcSEcCtD
Gefitinib—Cisapride—CYP1A2—chronic obstructive pulmonary disease	0.000195	0.0369	CrCbGaD
Gefitinib—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000195	0.00243	CcSEcCtD
Gefitinib—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000194	0.00242	CcSEcCtD
Gefitinib—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000191	0.00238	CcSEcCtD
Gefitinib—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000191	0.00238	CcSEcCtD
Gefitinib—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000189	0.00236	CcSEcCtD
Gefitinib—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000189	0.00236	CcSEcCtD
Gefitinib—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000187	0.00234	CcSEcCtD
Gefitinib—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000186	0.00232	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000183	0.00228	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000183	0.00228	CcSEcCtD
Gefitinib—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000183	0.00228	CcSEcCtD
Gefitinib—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000183	0.00228	CcSEcCtD
Gefitinib—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000182	0.00226	CcSEcCtD
Gefitinib—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000182	0.00226	CcSEcCtD
Gefitinib—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000182	0.00226	CcSEcCtD
Gefitinib—Pain—Formoterol—chronic obstructive pulmonary disease	0.000182	0.00226	CcSEcCtD
Gefitinib—Iloperidone—CYP1A2—chronic obstructive pulmonary disease	0.00018	0.0341	CrCbGaD
Gefitinib—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00018	0.00224	CcSEcCtD
Gefitinib—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000179	0.00223	CcSEcCtD
Gefitinib—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000179	0.00223	CcSEcCtD
Gefitinib—Pain—Montelukast—chronic obstructive pulmonary disease	0.000178	0.00222	CcSEcCtD
Gefitinib—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000178	0.00221	CcSEcCtD
Gefitinib—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000176	0.00219	CcSEcCtD
Gefitinib—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000176	0.00219	CcSEcCtD
Gefitinib—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000175	0.00218	CcSEcCtD
Gefitinib—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000174	0.00217	CcSEcCtD
Gefitinib—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000174	0.00216	CcSEcCtD
Gefitinib—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000174	0.00216	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000173	0.00216	CcSEcCtD
Gefitinib—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000173	0.00215	CcSEcCtD
Gefitinib—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000172	0.00214	CcSEcCtD
Gefitinib—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000172	0.00214	CcSEcCtD
Gefitinib—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00017	0.00212	CcSEcCtD
Gefitinib—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000169	0.0021	CcSEcCtD
Gefitinib—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000169	0.0021	CcSEcCtD
Gefitinib—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000168	0.00209	CcSEcCtD
Gefitinib—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000168	0.00209	CcSEcCtD
Gefitinib—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000168	0.00209	CcSEcCtD
Gefitinib—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000168	0.00209	CcSEcCtD
Gefitinib—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000167	0.00209	CcSEcCtD
Gefitinib—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000166	0.00207	CcSEcCtD
Gefitinib—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000166	0.00207	CcSEcCtD
Gefitinib—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000166	0.00207	CcSEcCtD
Gefitinib—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000165	0.00206	CcSEcCtD
Gefitinib—Cisapride—HTR2A—chronic obstructive pulmonary disease	0.000165	0.0311	CrCbGaD
Gefitinib—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000165	0.00205	CcSEcCtD
Gefitinib—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000165	0.00205	CcSEcCtD
Gefitinib—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.00204	CcSEcCtD
Gefitinib—ABCB1—trachea—chronic obstructive pulmonary disease	0.000163	0.00482	CbGeAlD
Gefitinib—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000163	0.00203	CcSEcCtD
Gefitinib—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000162	0.00202	CcSEcCtD
Gefitinib—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.00199	CcSEcCtD
Gefitinib—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.00198	CcSEcCtD
Gefitinib—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.00198	CcSEcCtD
Gefitinib—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000157	0.00195	CcSEcCtD
Gefitinib—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000157	0.00195	CcSEcCtD
Gefitinib—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000156	0.00195	CcSEcCtD
Gefitinib—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000156	0.00194	CcSEcCtD
Gefitinib—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000155	0.00193	CcSEcCtD
Gefitinib—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000153	0.00191	CcSEcCtD
Gefitinib—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000152	0.0019	CcSEcCtD
Gefitinib—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000152	0.0019	CcSEcCtD
Gefitinib—Iloperidone—HTR2A—chronic obstructive pulmonary disease	0.000152	0.0287	CrCbGaD
Gefitinib—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00015	0.00187	CcSEcCtD
Gefitinib—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00015	0.00187	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.00015	0.00187	CcSEcCtD
Gefitinib—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000149	0.00186	CcSEcCtD
Gefitinib—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000148	0.00184	CcSEcCtD
Gefitinib—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000147	0.00183	CcSEcCtD
Gefitinib—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000145	0.00181	CcSEcCtD
Gefitinib—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000145	0.00181	CcSEcCtD
Gefitinib—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000145	0.0018	CcSEcCtD
Gefitinib—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000144	0.0018	CcSEcCtD
Gefitinib—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000144	0.00179	CcSEcCtD
Gefitinib—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000142	0.00177	CcSEcCtD
Gefitinib—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000142	0.00177	CcSEcCtD
Gefitinib—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000137	0.00171	CcSEcCtD
Gefitinib—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000135	0.00168	CcSEcCtD
Gefitinib—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000135	0.00168	CcSEcCtD
Gefitinib—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000134	0.00167	CcSEcCtD
Gefitinib—Rash—Formoterol—chronic obstructive pulmonary disease	0.000134	0.00167	CcSEcCtD
Gefitinib—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000134	0.00167	CcSEcCtD
Gefitinib—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000134	0.00167	CcSEcCtD
Gefitinib—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000133	0.00166	CcSEcCtD
Gefitinib—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000132	0.00165	CcSEcCtD
Gefitinib—Rash—Montelukast—chronic obstructive pulmonary disease	0.000131	0.00163	CcSEcCtD
Gefitinib—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000131	0.00163	CcSEcCtD
Gefitinib—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000129	0.0016	CcSEcCtD
Gefitinib—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000128	0.00159	CcSEcCtD
Gefitinib—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000127	0.00158	CcSEcCtD
Gefitinib—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000127	0.00158	CcSEcCtD
Gefitinib—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000126	0.00157	CcSEcCtD
Gefitinib—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000126	0.00157	CcSEcCtD
Gefitinib—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000126	0.00157	CcSEcCtD
Gefitinib—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000124	0.00154	CcSEcCtD
Gefitinib—Erlotinib—ALB—chronic obstructive pulmonary disease	0.00012	0.0226	CrCbGaD
Gefitinib—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000119	0.00148	CcSEcCtD
Gefitinib—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000118	0.00147	CcSEcCtD
Gefitinib—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000118	0.00147	CcSEcCtD
Gefitinib—ABCB1—lung—chronic obstructive pulmonary disease	0.000117	0.00346	CbGeAlD
Gefitinib—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000113	0.00141	CcSEcCtD
Gefitinib—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.00011	0.00137	CcSEcCtD
Gefitinib—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000107	0.00133	CcSEcCtD
Gefitinib—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000105	0.00131	CcSEcCtD
Gefitinib—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000104	0.0013	CcSEcCtD
Gefitinib—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000102	0.00128	CcSEcCtD
Gefitinib—Pain—Prednisolone—chronic obstructive pulmonary disease	9.84e-05	0.00123	CcSEcCtD
Gefitinib—Anaemia—Prednisone—chronic obstructive pulmonary disease	9.47e-05	0.00118	CcSEcCtD
Gefitinib—Angioedema—Prednisone—chronic obstructive pulmonary disease	9.36e-05	0.00117	CcSEcCtD
Gefitinib—Malaise—Prednisone—chronic obstructive pulmonary disease	9.24e-05	0.00115	CcSEcCtD
Gefitinib—Urticaria—Prednisolone—chronic obstructive pulmonary disease	9.14e-05	0.00114	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	8.66e-05	0.00108	CcSEcCtD
Gefitinib—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	8.48e-05	0.00106	CcSEcCtD
Gefitinib—Infection—Prednisone—chronic obstructive pulmonary disease	8.31e-05	0.00103	CcSEcCtD
Gefitinib—Shock—Prednisone—chronic obstructive pulmonary disease	8.23e-05	0.00102	CcSEcCtD
Gefitinib—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	8.2e-05	0.00102	CcSEcCtD
Gefitinib—Skin disorder—Prednisone—chronic obstructive pulmonary disease	8.12e-05	0.00101	CcSEcCtD
Gefitinib—Anorexia—Prednisone—chronic obstructive pulmonary disease	7.97e-05	0.000993	CcSEcCtD
Gefitinib—Vandetanib—ALB—chronic obstructive pulmonary disease	7.88e-05	0.0149	CrCbGaD
Gefitinib—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	7.27e-05	0.000905	CcSEcCtD
Gefitinib—Rash—Prednisolone—chronic obstructive pulmonary disease	7.26e-05	0.000904	CcSEcCtD
Gefitinib—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	7.25e-05	0.000903	CcSEcCtD
Gefitinib—Fatigue—Prednisone—chronic obstructive pulmonary disease	7.21e-05	0.000898	CcSEcCtD
Gefitinib—Constipation—Prednisone—chronic obstructive pulmonary disease	7.15e-05	0.000891	CcSEcCtD
Gefitinib—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	6.84e-05	0.000852	CcSEcCtD
Gefitinib—Nausea—Prednisolone—chronic obstructive pulmonary disease	6.84e-05	0.000851	CcSEcCtD
Gefitinib—Urticaria—Prednisone—chronic obstructive pulmonary disease	6.64e-05	0.000827	CcSEcCtD
Gefitinib—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	6.61e-05	0.000823	CcSEcCtD
Gefitinib—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	6.61e-05	0.000823	CcSEcCtD
Gefitinib—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	6.16e-05	0.000767	CcSEcCtD
Gefitinib—Asthenia—Prednisone—chronic obstructive pulmonary disease	6e-05	0.000747	CcSEcCtD
Gefitinib—Pruritus—Prednisone—chronic obstructive pulmonary disease	5.92e-05	0.000737	CcSEcCtD
Gefitinib—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	5.72e-05	0.000713	CcSEcCtD
Gefitinib—Vomiting—Prednisone—chronic obstructive pulmonary disease	5.32e-05	0.000662	CcSEcCtD
Gefitinib—Rash—Prednisone—chronic obstructive pulmonary disease	5.27e-05	0.000657	CcSEcCtD
Gefitinib—Dermatitis—Prednisone—chronic obstructive pulmonary disease	5.27e-05	0.000656	CcSEcCtD
Gefitinib—Nausea—Prednisone—chronic obstructive pulmonary disease	4.97e-05	0.000619	CcSEcCtD
Gefitinib—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.16e-05	0.000152	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.16e-05	0.000152	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.16e-05	0.000151	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.15e-05	0.000151	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.15e-05	0.00015	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.14e-05	0.00015	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.14e-05	0.000149	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	1.13e-05	0.000148	CbGpPWpGaD
Gefitinib—MKNK1—Disease—TGFB1—chronic obstructive pulmonary disease	1.12e-05	0.000147	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.12e-05	0.000146	CbGpPWpGaD
Gefitinib—EGFR—Disease—KL—chronic obstructive pulmonary disease	1.12e-05	0.000146	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	1.11e-05	0.000145	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.1e-05	0.000145	CbGpPWpGaD
Gefitinib—MKNK1—Disease—EGFR—chronic obstructive pulmonary disease	1.1e-05	0.000144	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.09e-05	0.000143	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.09e-05	0.000143	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.08e-05	0.000141	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.07e-05	0.00014	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.06e-05	0.000139	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.06e-05	0.000138	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.06e-05	0.000138	CbGpPWpGaD
Gefitinib—ERBB3—Disease—SERPINE1—chronic obstructive pulmonary disease	1.06e-05	0.000138	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.05e-05	0.000138	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.05e-05	0.000138	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.05e-05	0.000138	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.04e-05	0.000136	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	1.03e-05	0.000135	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.03e-05	0.000135	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.01e-05	0.000133	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—EGFR—chronic obstructive pulmonary disease	1.01e-05	0.000132	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NOS3—chronic obstructive pulmonary disease	1.01e-05	0.000132	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CTGF—chronic obstructive pulmonary disease	1.01e-05	0.000132	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.01e-05	0.000132	CbGpPWpGaD
Gefitinib—ABCG2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	9.79e-06	0.000128	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.77e-06	0.000128	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD8A—chronic obstructive pulmonary disease	9.75e-06	0.000128	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.7e-06	0.000127	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	9.69e-06	0.000127	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.64e-06	0.000126	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	9.6e-06	0.000126	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	9.56e-06	0.000125	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	9.55e-06	0.000125	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MMP9—chronic obstructive pulmonary disease	9.48e-06	0.000124	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.42e-06	0.000123	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	9.35e-06	0.000122	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—IL6—chronic obstructive pulmonary disease	9.34e-06	0.000122	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	9.33e-06	0.000122	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL1B—chronic obstructive pulmonary disease	9.29e-06	0.000122	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.29e-06	0.000122	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.26e-06	0.000121	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—MMP1—chronic obstructive pulmonary disease	9.21e-06	0.000121	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	9.19e-06	0.00012	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—IL6—chronic obstructive pulmonary disease	9.12e-06	0.000119	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ERBB3—chronic obstructive pulmonary disease	9.07e-06	0.000119	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PLAU—chronic obstructive pulmonary disease	9.04e-06	0.000118	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—EGFR—chronic obstructive pulmonary disease	8.88e-06	0.000116	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	8.82e-06	0.000115	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	8.77e-06	0.000115	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—TGFB1—chronic obstructive pulmonary disease	8.75e-06	0.000115	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.58e-06	0.000112	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—EGFR—chronic obstructive pulmonary disease	8.58e-06	0.000112	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	8.57e-06	0.000112	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	8.51e-06	0.000111	CbGpPWpGaD
Gefitinib—MKNK1—Disease—IL6—chronic obstructive pulmonary disease	8.48e-06	0.000111	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.44e-06	0.00011	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	8.43e-06	0.00011	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	8.41e-06	0.00011	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	8.39e-06	0.00011	CbGpPWpGaD
Gefitinib—EGFR—Disease—ERBB3—chronic obstructive pulmonary disease	8.37e-06	0.00011	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NOS2—chronic obstructive pulmonary disease	8.31e-06	0.000109	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CRP—chronic obstructive pulmonary disease	8.29e-06	0.000109	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	8.27e-06	0.000108	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—IL6—chronic obstructive pulmonary disease	8.25e-06	0.000108	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.22e-06	0.000108	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.01e-06	0.000105	CbGpPWpGaD
Gefitinib—EGFR—Immune System—TLR4—chronic obstructive pulmonary disease	7.95e-06	0.000104	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	7.91e-06	0.000104	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.88e-06	0.000103	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	7.88e-06	0.000103	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	7.84e-06	0.000103	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KL—chronic obstructive pulmonary disease	7.82e-06	0.000102	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	7.81e-06	0.000102	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—IL6—chronic obstructive pulmonary disease	7.78e-06	0.000102	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.75e-06	0.000101	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL1B—chronic obstructive pulmonary disease	7.73e-06	0.000101	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.72e-06	0.000101	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.67e-06	0.0001	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	7.65e-06	0.0001	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.64e-06	0.0001	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.56e-06	9.9e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GCLC—chronic obstructive pulmonary disease	7.48e-06	9.79e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.43e-06	9.73e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.39e-06	9.68e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.32e-06	9.59e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TNF—chronic obstructive pulmonary disease	7.3e-06	9.55e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	7.22e-06	9.46e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.22e-06	9.45e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.12e-06	9.32e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—EGFR—chronic obstructive pulmonary disease	7.08e-06	9.27e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.06e-06	9.24e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	7e-06	9.17e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	6.99e-06	9.16e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NOS2—chronic obstructive pulmonary disease	6.98e-06	9.14e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.97e-06	9.13e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	6.94e-06	9.09e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.9e-06	9.03e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL6—chronic obstructive pulmonary disease	6.82e-06	8.93e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CTGF—chronic obstructive pulmonary disease	6.82e-06	8.93e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GCLC—chronic obstructive pulmonary disease	6.82e-06	8.92e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	6.81e-06	8.92e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.75e-06	8.83e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NOS3—chronic obstructive pulmonary disease	6.68e-06	8.74e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.67e-06	8.74e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—TGFB1—chronic obstructive pulmonary disease	6.67e-06	8.73e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.65e-06	8.71e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—IL6—chronic obstructive pulmonary disease	6.59e-06	8.63e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—EGFR—chronic obstructive pulmonary disease	6.53e-06	8.56e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.5e-06	8.5e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.48e-06	8.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.45e-06	8.44e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	6.33e-06	8.29e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.29e-06	8.23e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.26e-06	8.2e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CTGF—chronic obstructive pulmonary disease	6.22e-06	8.14e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.19e-06	8.1e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.16e-06	8.06e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.13e-06	8.02e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	6.12e-06	8.01e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.04e-06	7.91e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.01e-06	7.86e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	5.97e-06	7.82e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.94e-06	7.77e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	5.9e-06	7.73e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—EGFR—chronic obstructive pulmonary disease	5.89e-06	7.72e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—IL6—chronic obstructive pulmonary disease	5.89e-06	7.71e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—SERPINE1—chronic obstructive pulmonary disease	5.88e-06	7.7e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.88e-06	7.69e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.88e-06	7.69e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	5.86e-06	7.67e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.73e-06	7.5e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	5.7e-06	7.47e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.69e-06	7.45e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.66e-06	7.41e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.64e-06	7.39e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5.64e-06	7.39e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	5.63e-06	7.37e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NOS3—chronic obstructive pulmonary disease	5.61e-06	7.35e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	5.58e-06	7.31e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	5.58e-06	7.3e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.55e-06	7.27e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.47e-06	7.17e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	5.45e-06	7.13e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL6—chronic obstructive pulmonary disease	5.44e-06	7.12e-05	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	5.29e-06	6.93e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.28e-06	6.91e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.25e-06	6.87e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.24e-06	6.86e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.21e-06	6.82e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	5.2e-06	6.81e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—IL6—chronic obstructive pulmonary disease	5.2e-06	6.81e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL1B—chronic obstructive pulmonary disease	5.17e-06	6.77e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.17e-06	6.77e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.14e-06	6.73e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	5.14e-06	6.72e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.1e-06	6.68e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	5.09e-06	6.67e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.09e-06	6.66e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.04e-06	6.6e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—IL6—chronic obstructive pulmonary disease	5.02e-06	6.58e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.02e-06	6.57e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.84e-06	6.34e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.83e-06	6.33e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.82e-06	6.31e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—chronic obstructive pulmonary disease	4.81e-06	6.3e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.78e-06	6.26e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.75e-06	6.22e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.73e-06	6.19e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.71e-06	6.17e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.71e-06	6.17e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.69e-06	6.14e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.67e-06	6.11e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.62e-06	6.04e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ALB—chronic obstructive pulmonary disease	4.59e-06	6e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.58e-06	5.99e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6—chronic obstructive pulmonary disease	4.53e-06	5.93e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TGFB1—chronic obstructive pulmonary disease	4.42e-06	5.78e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.39e-06	5.75e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—NOS3—chronic obstructive pulmonary disease	4.39e-06	5.74e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.29e-06	5.62e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.23e-06	5.54e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.23e-06	5.54e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.19e-06	5.48e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.16e-06	5.45e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.13e-06	5.41e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.12e-06	5.39e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.99e-06	5.22e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.95e-06	5.17e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.94e-06	5.16e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.93e-06	5.14e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.91e-06	5.12e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.89e-06	5.1e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.89e-06	5.09e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.86e-06	5.05e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.85e-06	5.04e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.84e-06	5.03e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.81e-06	4.99e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.74e-06	4.89e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.72e-06	4.87e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFB1—chronic obstructive pulmonary disease	3.71e-06	4.86e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	3.68e-06	4.82e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.65e-06	4.78e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.65e-06	4.78e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—chronic obstructive pulmonary disease	3.63e-06	4.76e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.63e-06	4.75e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.59e-06	4.71e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.52e-06	4.6e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.49e-06	4.56e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.44e-06	4.5e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.41e-06	4.46e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	3.36e-06	4.4e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.31e-06	4.34e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	3.29e-06	4.3e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.2e-06	4.19e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.15e-06	4.13e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	3.14e-06	4.12e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ALB—chronic obstructive pulmonary disease	3.1e-06	4.06e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.09e-06	4.05e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—chronic obstructive pulmonary disease	3.03e-06	3.96e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	2.97e-06	3.89e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.93e-06	3.83e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.83e-06	3.71e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—chronic obstructive pulmonary disease	2.8e-06	3.66e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NOS3—chronic obstructive pulmonary disease	2.71e-06	3.54e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.6e-06	3.4e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.58e-06	3.38e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.54e-06	3.33e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	2.54e-06	3.33e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	2.48e-06	3.25e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	2.43e-06	3.18e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	2.37e-06	3.11e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.37e-06	3.1e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	2.34e-06	3.06e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	2.32e-06	3.03e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.25e-06	2.94e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	2.24e-06	2.93e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	2.22e-06	2.9e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.14e-06	2.8e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.96e-06	2.56e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.53e-06	2e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.46e-06	1.91e-05	CbGpPWpGaD
